

BPH and sexual dysfunction

Sexual dysfunction is common from age 60 onwards

Fifty percent of men between the ages of 60 and 69 can no longer achieve an erection or can achieve only a reduced erection (known as ED or erectile dysfunction.)

In the same age group, 49% state that they have no or only a reduced ejaculation.¹

BPH = high risk of sexual dysfunction

The main risk factor for erectile dysfunction is age followed by moderate or severe BPH symptoms – ahead of diabetes, high blood pressure and heart complaints.¹

Sexual dysfunction during standard medical therapy

The standard medical therapy for BPH can further exacerbate these sexual dysfunction. Up to 30% of patients taking alpha blockers have ejaculation disorders² and up to 38% of patients on 5- α -reductase inhibitors suffer from erectile dysfunction³. Men also repeatedly discontinue the standard therapy for BPH because of sexual dysfunction.⁴

A.Vogel Sabalasan® Prostate 1 not only improves the symptoms of BPH, but a new clinical study has also shown that brings an improvement in all areas of sexual dysfunction.⁵

¹Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44:637

²Carbone DJ, Jr., Hodges S. 2003. Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life. Int J Impot Res 15(4): 299-306


³Erdemir F, Harbin A, Hellstrom WJ. 2008. 5-alpha reductase inhibitors and erectile dysfunction: the connection. J Sex Med 5(12): 2917-2924

⁴Roehrborn CG. Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, Erectile Dysfunction, and Phosphodiesterase-5 Inhibitors. Rev Urol. 2004 Summer; 6(3): 121–127



Sabalasan® Prostate 1: Clinical study on sexual dysfunction

Results of the brief Sexual Function Inventory score (bSFI)¹ The bSFI comprises 11 questions in 5 areas.




In all areas of the bSFI test, a significant improvement was achieved after 8 weeks of treatment.





Sabalasan® Prostate 1 improves BPH symptoms

Improvement in IPSS (International Prostate Symptom Score)¹




The BPH symptoms decreased by half from 14.4 (= moderate symptoms) to 6.9 (= mild symptoms) after 8 weeks of treatment with A.Vogel Sabalasan® Prostate 1.






Sabalasan® Prostate 1 improves sexual dysfunction

Improvement in bSFI (brief Sexual Function Inventory) and Urolife BPH Quality of Life-9 total scores¹





The total score on the brief Sexual Function Inventory improved by 40% and the results of the Urolife Quality of Life Score by 35% after 8 weeks of treatment with A.Voqel Sabalasan® Prostate 1.


Therapeutic benefits for the user:


- Significant improvement in BPH symptoms
- Significant improvement in all areas of sexual dysfunction
- Significantly higher quality of life



Sabalasan® Prostate 1 well tolerated


Excellent tolerability¹





96.1% of patients and investigators rated the tolerability as "very good" or "good."

Herbal remedies preferred¹



97% of patients would prefer a herbal to a synthetic remedy with the same efficacy and tolerability.



Sabalasan® Prostate 1 is also cost-effective

Comparison of daily cost of treatment in Canada, sildenafil (Viagra®) and saw palmetto extract (Sabalasan® Prostate 1)¹



Therapeutic benefits for the user:

- Comparable efficacy to standard medical therapy with outstanding tolerability
- The vast majority of men prefer herbal remedies
- Good compliance: only 1 capsule Sabalasan® Prostate 1 orally per day
- Economical, non-prescription, available from pharmacies

